Great. Steve. Thanks,
a just is slide our of first QX financials. The summary
you sense progress across the a at column we get the the right, of the metric of look year-on-year change to made business. If you'll every
different Steve revenues to As of faster the a growth P&L the XXXX. call, the the at in covered gross top moved margins with large level in increase in even
made significantly, we growth, we in future a per of meaningful substantial narrowed as generated Even loss and share cash. investments our amount
that recall convertible the we notes You'll in QX. early retired
just under of the cash from no from billion credit the sheet effectively us and that So in leaves relationship line $X debt balance aside UBS. on with
Okay.
XXXX the on the the slide. revenue to of call. guidance get the on Steve guide next the Let's at touched top
to billion off. guiding start the be to $X.XX year to revenues in $X.XX pleased billion to are We
in seeing assumption continue guide XXXX. we've the this rolling for trends the base few just quarters is last Our really into been having positive
And set share and [ health ASPs market consistently guide We've and to presumes in to end-market capture to steady we revenue in seen means X,XXX ] forecast any now target. unit grow The stable ] Oregon above guide modestly Signatera not true-ups. XX,XXX obviously course, in previously to growth we we've ] X,XXX growth XX,XXX attempt the women's [ volume [ of continued a also threshold clinical volume sequentially. grow growth will XXXX. expect Signatera to ] The that does sequential Health. continue outpace as That [ level
the the on fact can and they can good underlying that true-ups lumpy think While guide that we collections, what execution means be based business we just represent we the think deliver. will unpredictable on cash
our have this beginning Consistent guide with we several year, we of the meaningful upside potential. that acknowledging at setting philosophy, are the of sources
we For and that us that guide those us to long this health a through our growth is that organic we health followed women's for ASPs continued know you women's in year example, could described. of stable John are a actually see time for cautiously to signal, efforts, ASPs fairly have own in bullish optimistic as
We we haven't outcome, XXq time screening, carrier course, guidelines lot on if of positive. of great the we be a another ACOG would dwelling or that of and either to spent feedback get expanded continues get upside both be recently. But on
readouts Solomon on the Health upside accelerated the would and extremely of to TAP covered those both and we adoption results some Oregon guide. trial Renasight impactful data on of clinical have and Prospera be the back of
offers of pricing year. this model clinical largest realized upside and Signatera adoption in of sources setting the pace the the of potential the course, to Of
will everything from like States. there better example, sources And Between position significant We've the upside been ex cancer much several a our at way posted at growth margin the business. we a laws. in guidance, the the The we true-ups. currently Signatera in executing in into very to and CELEBREX X-year investments and is flowing overall the change We The QX reimbursement. the CIRCULATE, with can and products. are of come treated to half operations never ASCO biomarker XX% major survival the optimistic readout GI, data consistent broaden with of in we level the better sales either guidelines high adoption. of in some additional of see level The rates results the guide cautiously allowed course, guide Advantage realized better-than-expected shoots United do growth for we presumes in several and with Signatera, biomarker green pricing require margin ASP from remain state sources but can or we any presumes NCC in gross modest above any gross does Medicare believe revenue, second traction margin to could the for from some progress not significant continued
are gross X A note the these the margin of neither MRD we caution have products of complementary is that unit economics. in optimize on which launching menu,
for Our volumes tumor-naive of to the largely uptake broader a both offering of patients. MRD genome I and on some a for to modest create the we If core expectations, argue set either and presumes that avail healthy their volume of a Signatera is as headwind menu margins, from from the customers of signal short-term us that themselves the model expect be franchise. very would would uptake backbone longer-term uptake Signatera our this but product, existing additive exceeds development
demonstrate the lines covered, innovation, the and not trial across our in taking and clinical We are Steve foot off pursuit hold gas of As business. that customer our could we results SG&A service R&D in grew expenses if held we to our and completely expenses all XX%. at flat growth and Indeed, look in XXXX, revenues XXXX. it wouldn't approximately XXXX or affect flat XXXX, still you that year back great
we incremental patients early platform mandate think Steve we in unveiled best us deliver promising We our year and further from some our next invest years to very field ahead dollar already are core the data possible to to this puts the the detection made but seeing have core in high spend for in our early now XXXX is we to investments year ECV we and offering ROICs cancer today, products. in the of come. every
again returns cash are ensuring a manage with a deliver are flow on remain business result XXXX. investments, these will to we and excellent We getting goal to the in going on we focused positive
One Okay. its guide just the in slide revenue proper context. to put more
are in not XXXX As any guiding true-ups I the guidance. we mentioned, to
to evaluate roughly stripped on reimbursement revenue the likely drive the review implied well. volumes, I moderate growth from moderates, appeals the apples-to-apples an that have basis, true-ups out. and as from framework is with remove do And test the results true-ups I expect at Accordingly, results, XXXX we progress when for understanding we the midpoint. note to older as as to on ASP quarterly Although you'll continue true-ups growth XX% will the some guide the true-up simplest you think the is then rate
other point operating exceeding guide year. a businesses of target current of most at the with this the is through growth starting scale, as this the are our While than we faster course goal setting much this
let's up questions. it Operator? that, With for open Okay.
